Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
JNCI Cancer Spectrum · 09.01.2026 · 10 (1)
DOI: 10.1093/jncics/pkag003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.01.2026. Verfasst von Reo Omori und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophagogastric Junction, Immune Checkpoint Inhibitors, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The addition of immune checkpoint inhibitors (ICIs) to perioperative treatment for resectable gastric or gastroesophageal junction (GEJ) cancers has shown promising results. However, current pivotal trials (KEYNOTE-585 and MATTERHORN) have reported conflicting survival outcomes. To clarify their therapeutic value, we conducted a meta-analysis evaluating the efficacy and safety of adding ICIs to this population.
Methods
PubMed, Embase, and major oncology conference abstracts were systematically searched for randomized controlled trials (RCTs) comparing ICIs plus chemotherapy versus chemotherapy alone in patients with resectable gastric or GEJ adenocarcinoma. Outcomes included pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and treatment-related adverse events (TRAEs). Risk differences (RDs) and hazard ratios (HRs) were pooled using a fixed-effect model meta-analysis.
Results
Seven RCTs involving 2510 patients were included. Compared with chemotherapy alone, chemoimmunotherapy significantly improved pCR (17.6% vs. 6.1%; RD = 0.11, 95% CI = 0.09 to 0.14, P < .001), EFS (HR = 0.76, 95% CI = 0.66 to 0.86, P < .001), and OS (HR = 0.82, 95% CI = 0.71 to 0.94, P = .005). Subgroup analyses showed statistically significant efficacy in PD-L1 positive tumors, whereas no significant benefit was observed in PD-L1 negative patients. Grade ≥3 TRAEs were not significantly increased with chemoimmunotherapy (66.1% vs. 62.7%; RD = 0.04, 95% CI = 0.00 to 0.08, P = .08).
Conclusions
The addition of ICIs to perioperative chemotherapy improves pathological and survival outcomes in resectable gastric or GEJ cancers, particularly in PD-L1 positive populations, without increasing grade ≥3 TRAEs. These findings support chemoimmunotherapy as a promising curative strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
- Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Fujita Health University Hospital, Toyoake, Japan.
- Icahn School of Medicine at Mount Sinai, Morningside Hospital, New York, NY, United States.
- GI Medical Oncology, Miami Cancer Institute, Miami, FL, United States.
ORCID-Profile: Reo Omori, Yu Fujiwara, Takumi Sato, Sarbajit Mukherjee
Zitieren
APA
Omori, R., Fujiwara, Y., Tokunaga, K., Sato, T., & Mukherjee, S. (2026). Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. JNCI Cancer Spectrum, 10(1). https://doi.org/10.1093/jncics/pkag003
Vancouver
Omori R, Fujiwara Y, Tokunaga K, Sato T, Mukherjee S. Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. JNCI Cancer Spectrum. 2026;10(1). doi:10.1093/jncics/pkag003
BibTeX
@article{Omori2026,
author = {Omori, Reo and Fujiwara, Yu and Tokunaga, Kota and Sato, Takumi and Mukherjee, Sarbajit},
title = {Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {1},
doi = {10.1093/jncics/pkag003}
}
EUVIMED